| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Commercial Officer | Chief Commercial Officer
3 companies
Wiley Matthew T. serves as a Chief Commercial Officer at DFTX and has filed Form 4s across 3 companies. Across recent SEC filings that breaks down to 0 buys and 5 sells. Those positions are worth an estimated $10.3M at current prices.
Historically, Wiley Matthew T.'s trades have earned a strong insider score of 82/100 across 4 rated trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +82.6%.
The biggest single holding is DFTX (~$7.1M) as Chief Commercial Officer. The recent filings there lean toward selling, a net 2,867 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 25, 2026 | DFTX Definium Therapeutics, Inc. | Chief Commercial Officer | Sell | 2,867 | $45.03 | $129,101.01 | -1.6% | - | - | |
| Oct 3, 2024 | BTAI Bioxcel Therapeutics, Inc. | Chief Commercial Officer | Sell | 6,272 | $0.55 | $3,449.60 | -24.8% | -28.7% | -71.3% | |
| Sep 16, 2024 | BTAI Bioxcel Therapeutics, Inc. | Chief Commercial Officer | Sale+OE | 215 | $0.69 | $148.52 | -5.1% | -36.5% | -70.8% | |
| Jun 17, 2024 | BTAI Bioxcel Therapeutics, Inc. | Chief Commercial Officer | Sale+OE | 244 | $1.26 | $308.10 | -6.5% | -51.9% | -92.3% | |
| Apr 4, 2024 | BTAI Bioxcel Therapeutics, Inc. | Chief Commercial Officer | Sale+OE | 1,008 | $2.64 | $2,656.18 | -25.2% | -59.9% | -96.2% |